FindTrial
Sign In

Olaparib tablet

DRUG5 trials

Sponsors

Hongqian Guo, Sunnybrook Health Sciences Centre, Fondazione Ricerca Traslazionale, Alexander B Olawaiye, MD, Tianjin Medical University Second Hospital

Conditions

High Grade Serous CarcinomaMetastatic Prostate CancerNon-small-cell Lung Cancer PatientsOvarian CancerPrecision MedicineProstate CancerProstate CarcinomaSolid Tumor

Phase 1

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
Active, not recruitingNCT05358639
Sunnybrook Health Sciences CentreHigh Grade Serous Carcinoma, Ovarian Cancer, Triple Negative Breast Cancer
Start: 2022-11-09End: 2025-04-28Target: 36Updated: 2024-11-18

Phase 2

The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation
NCT05167175
Hongqian GuoMetastatic Prostate Cancer, Prostate Cancer, Prostate Carcinoma
Start: 2022-03-01End: 2024-12-01Target: 30Updated: 2022-10-25
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
RecruitingNCT05568212
Fondazione Ricerca TraslazionaleNon-small-cell Lung Cancer Patients
Start: 2022-05-02End: 2027-05-31Target: 176Updated: 2025-12-01
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
WithdrawnNCT06120972
Alexander B Olawaiye, MDOvarian Cancer
Start: 2024-01-17End: 2029-12-31Updated: 2025-02-12
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
RecruitingNCT06739395
Tianjin Medical University Second HospitalPrecision Medicine, Solid Tumor
Start: 2024-11-01End: 2027-05-01Target: 300Updated: 2024-12-18

Related Papers

A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact.
Journal of Clinical Oncology2025-02-10
PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.
Journal of Clinical Oncology2024-06-01
Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.
Journal of Clinical Oncology2023-06-014 citations
Abstract 206: Organoid models for predicting drug response in high grade serous and triple negative breast cancer
Cancer Research2023-04-04